Leerink Partnrs Raises Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Kura Oncology in a report issued on Thursday, November 21st. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($2.19) for the year, up from their prior forecast of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

KURA has been the topic of a number of other reports. Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Trading Down 1.9 %

KURA opened at $10.75 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company’s 50 day simple moving average is $17.68 and its two-hundred day simple moving average is $19.60. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The firm has a market capitalization of $835.96 million, a price-to-earnings ratio of -4.56 and a beta of 0.86.

Institutional Trading of Kura Oncology

Institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in shares of Kura Oncology in the third quarter worth $25,000. Aaron Wealth Advisors LLC grew its stake in shares of Kura Oncology by 2.4% in the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after acquiring an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Kura Oncology by 17.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.